Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-?, CXCR4, CSF-1R, CD47-SIRP?, adenosine pathway & STING 2018
Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-?, CXCR4, CSF-1R, CD47-SIRP?, adenosine pathway & STING 2018
This Competitive Intelligence report analyzes the competitive field of modulators of the tumor microenvironment via IDO & TDO, TGF-beta/R, CXCR4, novel chemokines, CSF-1R, CD47-SIRPalpha, adenosine pathway incl. CD73/CD39 and STING as of July 2018 in a tabulated format with structured listings of industry-relevant data. The report describes the lead indications of each unique molecule in the most advanced R&D stage. The mainly selective, but also bispecific new molecular entities modulate the tumor microenvironment by targeting
The report includes a compilation of currently active projects in research and development of new molecular entities modulating the tumor microenvironment by targeting IDO & TDO, TGF-beta/R, CXCR4, novel chemokines, CSF-1R, CD47-SIRPalpha, adenosine pathway incl. CD73/CD39 and STING. In addition, the report lists company-specific R&D pipelines of modulators of the tumor microenvironment. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
This Competitive Intelligence report analyzes the competitive field of modulators of the tumor microenvironment via IDO & TDO, TGF-beta/R, CXCR4, novel chemokines, CSF-1R, CD47-SIRPalpha, adenosine pathway incl. CD73/CD39 and STING as of July 2018 in a tabulated format with structured listings of industry-relevant data. The report describes the lead indications of each unique molecule in the most advanced R&D stage. The mainly selective, but also bispecific new molecular entities modulate the tumor microenvironment by targeting
- IDO (Indoleamine 2,3-dioxygenase
- TDO (Tryptophan 2,3 dioxygenase)
- TGF-?/R (Transforming Growth Factor beta/Receptor)
- CXCR4 (Chemokine Receptor Type 4)
- Novel Chemokines (e.g. CCR2; CCR4, CXCL2, CXCR2, IL-8)
- CSF-1R (Colony Stimulating Factor-1 Receptor)
- CD47 – SIRP? (Signal Regulatory Protein Alpha)
- Adenosine Pathway: Adenosine 2A Receptor (A2AR), CD73, CD39 & adenosine
- STING (STimulator of INterferon Genes) Receptor
- Others (e.g. arginase
The report includes a compilation of currently active projects in research and development of new molecular entities modulating the tumor microenvironment by targeting IDO & TDO, TGF-beta/R, CXCR4, novel chemokines, CSF-1R, CD47-SIRPalpha, adenosine pathway incl. CD73/CD39 and STING. In addition, the report lists company-specific R&D pipelines of modulators of the tumor microenvironment. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target/Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1) TUMOR MICROENVIRONMENT MODULATION VIA IDO, TGF-?, CXCR4, CSF-1R, CD47-SIRP?, ADENOSINE PATHWAY & STING 2018
1a) IDO & TDO Inhibitors
First-Generation Selective IDO-1 Inhibitors
Novel Selective IDO-1 Inhibitors
Dual IDO/TDO Inhibitors
Selective TDO Inhibitors
Other Approaches for IDO or TDO Inhibition
1b) TGF-beta Inhibitors
Indirect TGF-beta Inhibition
Selective TGF-beta1 Inhibitors
Selective TGF-beta2 Inhibitors
Dual or Triple TGF-beta Inhibitors
Bispecific TGF-beta Inhibition
1c) CXCR4 Antagonists & CXCL2/SDF-1 Inhibitors
CXCR4 Antagonists
CXCL12/SDF-1 Inhibitors
1d) Novel Chemokine Inhibitors & Chemokine Receptor Antagonists
Interleukin-8/CXCL8 Inhibitors & CXCR2/CXCR1 Antagonists
Other Interleukin Inhibitors
CCR2/CCR5 Antagonists
CCR4 Antagonists
1e) CSF-1R Antagonists & CSF-1 Inhibitors
Multi-Specific CSF-1R Tyrosine Kinase Inhibitors
Selective CSF-1R Antagonists and CSF-1 Inhibitors
1f) CD47 Antagonists & SIRPalpha Inhibitors
CD47 Antagonists
SIRP? Inhibitors
Bispecific CD47 Antagonists
1g) Adenosine Pathway Modulation
Selective Adenosine A2A Receptor Antagonists
Selective Adenosine A2B Receptor Antagonists
Dual Adenosine A2 Receptor Antagonists
CD73 Ectoenzyme Inhibitors
CD39 Ectoenzyme Inhibitors
Other Approaches
1h) STING Agonists
2) CORPORATE TUMOR MICROENVIRONMENT MODULATOR R&D PIPELINES
1a) IDO & TDO Inhibitors
First-Generation Selective IDO-1 Inhibitors
Novel Selective IDO-1 Inhibitors
Dual IDO/TDO Inhibitors
Selective TDO Inhibitors
Other Approaches for IDO or TDO Inhibition
1b) TGF-beta Inhibitors
Indirect TGF-beta Inhibition
Selective TGF-beta1 Inhibitors
Selective TGF-beta2 Inhibitors
Dual or Triple TGF-beta Inhibitors
Bispecific TGF-beta Inhibition
1c) CXCR4 Antagonists & CXCL2/SDF-1 Inhibitors
CXCR4 Antagonists
CXCL12/SDF-1 Inhibitors
1d) Novel Chemokine Inhibitors & Chemokine Receptor Antagonists
Interleukin-8/CXCL8 Inhibitors & CXCR2/CXCR1 Antagonists
Other Interleukin Inhibitors
CCR2/CCR5 Antagonists
CCR4 Antagonists
1e) CSF-1R Antagonists & CSF-1 Inhibitors
Multi-Specific CSF-1R Tyrosine Kinase Inhibitors
Selective CSF-1R Antagonists and CSF-1 Inhibitors
1f) CD47 Antagonists & SIRPalpha Inhibitors
CD47 Antagonists
SIRP? Inhibitors
Bispecific CD47 Antagonists
1g) Adenosine Pathway Modulation
Selective Adenosine A2A Receptor Antagonists
Selective Adenosine A2B Receptor Antagonists
Dual Adenosine A2 Receptor Antagonists
CD73 Ectoenzyme Inhibitors
CD39 Ectoenzyme Inhibitors
Other Approaches
1h) STING Agonists
2) CORPORATE TUMOR MICROENVIRONMENT MODULATOR R&D PIPELINES
